The aim of this study was to develop a quantitative scale to assess levodopa-induced
dyskinesias (LIDs) in nonhuman primates using a video-based scoring system [Quantitative …

Rodent models of l-DOPA-induced dyskinesia (LID) are essential to investigate
pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary …

Abnormal involuntary movement (AIM) rating scales are frequently used to study the
mechanisms underlying l-DOPA-induced dyskinesia (LID) in 6-OHDA lesioned rodents and …

Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of
Parkinson's disease. The roadblocks that have hindered the development of new treatments …

Behavioral rating scales for dyskinesia in the non‐human primate are frequently used to
assess the efficacy of new treatments and to provide a clinical correlative with …

Levodopa dose and severity of Parkinson's disease (PD) are recognized risk factors for
levodopa-induced dyskinesia (LID) in humans. The purpose of the present study was to …

l-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of
Parkinson's Disease. A model of LID has recently been described in rats with unilateral 6 …

Current treatments for Parkinson's disease rely on a dopamine replacement strategy and are
reasonably effective, particularly in the early stages of the disease. However, chronic …

A common side effect of the pharmacotherapy for treatment of the movement disorder
Parkinson's disease is the development of l-DOPA-induced dyskinesia (LID). These are …

This unit provides detailed protocols for establishing rodent models of l‐DOPA‐induced
dyskinesia. The 6‐hydroxydopamine (6‐OHDA) lesion procedure is described in more detail …